Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia

Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia

Recent studies suggest a primary role of oxidative stress in an early phase of the pathogenesis of schizophrenia and a strong neurobiological link has been found between dopaminergic system dysfunction, microglia overactivation, and oxidative stress. Different risk factors for schizophrenia increase...

Full description

Bibliographic Details
Main Authors:	Giuseppe Caruso, Margherita Grasso, Annamaria Fidilio, Fabio Tascedda, Filippo Drago, Filippo Caraci
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	Pharmaceuticals
Subjects:	oxidative stress schizophrenia dopamine antioxidants antipsychotics inflammation
Online Access:	https://www.mdpi.com/1424-8247/13/12/457

Similar Items

Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
by: Sebastiano Alfio Torrisi, et al.
Published: (2020-11-01)

Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets
by: Anthony A. Grace, et al.
Published: (2023-08-01)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
by: Davide Amato, et al.
Published: (2019-05-01)

Antipsychotic-induced bone loss: the role of dopamine, serotonin and adrenergic receptor signalling
by: D. Kavindi Weerasinghe, et al.
Published: (2023-05-01)

Combination treatment with second generation antipsychotics other than clozapine
by: C. Schmidt-Kraepelin
Published: (2021-04-01)

Relationship between antipsychotic medication and aggressive events in patients with a psychotic disorder hospitalized for treatment
by: Georgia Tseligkaridou, et al.
Published: (2023-03-01)

Antipsychotic Induced Dopamine Receptor Supersensitivity and It’s Clinical Implications
by: Riko Lazuardi, et al.
Published: (2022-05-01)

Post‐hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long‐term study (Secondary Publication)
by: Jun Ishigooka, et al.
Published: (2020-06-01)

Onset of Action of Selected Second-Generation Antipsychotics (Pines)–A Systematic Review and Meta-Analyses
by: Rikke Meyer, et al.
Published: (2022-12-01)

Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment
by: Giuseppe De Simone, et al.
Published: (2023-04-01)

Comparison of antipsychotic prescribing practices following failure of antipsychotic monotherapy in the acute care setting
by: Kaitlyn Morgan, PharmD, BCPP, et al.
Published: (2023-01-01)

Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects
by: Antonio Rampino, et al.
Published: (2019-01-01)

Association between Changes in Total Antioxidant Levels and Clinical Symptom Improvement in Patients with Antipsychotic-Naïve First-Episode Schizophrenia after 3 Months of Risperidone Monotherapy
by: Keqiang Wang, et al.
Published: (2022-03-01)

The Role of Dopamine D3 Receptors, Dysbindin, and Their Functional Interaction in the Expression of Key Genes for Neuroplasticity and Neuroinflammation in the Mouse Brain
by: Veronica Rivi, et al.
Published: (2023-05-01)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
by: Olga Płaza, et al.
Published: (2022-12-01)

Canonical and Non-Canonical Antipsychotics’ Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia
by: Andrea de Bartolomeis, et al.
Published: (2023-03-01)

Unlocking the molecular mechanisms of antipsychotics – a new frontier for discovery
by: Heather Bowling, et al.
Published: (2016-07-01)

A esquizofrenia e seu tratamento farmacológico
by: Cilene Rejane Ramos Alves, et al.

A comparative study on metabolic syndrome in patients with schizophrenia treated using first-generation and second-generation antipsychotics
by: Dinesh Panati, et al.
Published: (2020-01-01)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
by: Hiroyuki Kamei
Published: (2022-11-01)

Antipsychotics for elderly with psychosis: Deprescribe or continue?
by: P. Mohr
Published: (2021-04-01)

Antipsychotic treatments; Focus on lurasidone
by: Tomiki eSumiyoshi
Published: (2013-08-01)

Clozapine: A special case of an atypical antipsychotic
by: Elina Marinho
Published: (2024-04-01)

Hormonal alterations due to antipsychotic-related hyperprolactinemia
by: A.L. Montejo, et al.
Published: (2022-06-01)

Identification of Antipsychotic Side Effects with Glassgow Antipsychotic Side-Effect Scale (GASS)
by: Dita Hasni, et al.
Published: (2020-08-01)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
by: M. Lähteenvuo, et al.
Published: (2021-04-01)

Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews
by: Tamara Melnik, et al.

The Effect of Menopause on Antipsychotic Response
by: Alexandre González-Rodríguez, et al.
Published: (2022-10-01)

Atypical antipsychotics in the treatment of schizophrenia
by: Swiss Medical Weekly
Published: (2003-02-01)

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
by: Miura I, et al.
Published: (2023-09-01)

Esquizofrenia: quarenta anos da hipótese dopaminérgica sob a ótica da Química Medicinal
by: Menegatti Ricardo, et al.
Published: (2004-01-01)

Atypical Antipsychotics Induced Metabolic Syndrome
by: Aysegul Demirel, et al.
Published: (2015-03-01)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
by: O. Vasiliu
Published: (2022-06-01)

Antipsychotic medication non-adherence among schizophrenia patients in Central Ethiopia
by: Minale Tareke, et al.
Published: (2018-03-01)

Evaluation of naltrexone augmentation to the antipsychotic drugs on positive and negative symptoms of schizophrenia
by: Javad Setareh, et al.
Published: (2008-01-01)

Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications
by: M S Karthik, et al.
Published: (2014-01-01)

Assessment of electroencephalography modification by antipsychotic drugs in patients with schizophrenia spectrum disorders using frontier orbital theory: A preliminary study
by: Takashi Ozaki, et al.
Published: (2023-06-01)

Myoclonic seizures induced by antipsychotic drugs: A case series and literature review (eng)
by: Taylan Altıparmak, et al.
Published: (2022-05-01)

Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside
by: Mujeeb U. Shad
Published: (2021-06-01)

Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia
by: Kristian S. Hill, et al.
Published: (2009-04-01)